Actively Recruiting
Effect of a Daily Supplement on Plasma PAI-1 Levels
Led by University of California, Los Angeles · Updated on 2026-03-13
35
Participants Needed
2
Research Sites
40 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Under physiological stress either due to the development of a disease such as diabetes or simply from aging, the endothelial cells can be impacted and become dysfunctional, thereby impairing their ability to make NO and even promoting the development of blood clots. When such endothelial dysfunction occurs, it may be a precursor for the future development of cardiovascular (CV) disease like hypertension or coronary artery disease later on in life in these patients. Therefore, the ability to enhance the local production or availability of NO within such affected blood vessels in patients identified as prone to endothelial dysfunction could play a positive role in either preventing or delaying the onset of endothelial dysfunction and subsequent CV disease in such patients. RM is an oral supplement consisting of natural ingredients and the amino acid, L-citrulline. In laboratory experiments with cells from the inner lining of blood vessels, the four components of RM have been shown to increase the concentration of NO and decrease the levels of some aging markers. In our recently completed study (manuscript currently in review), 31 young men and women took the supplement for 14 days and had no serious side effects. The supplement caused the expected potentially beneficial dilation of the blood vessels and decrease in the levels of Plasminogen Activator Inhibitor-1 (PAI-1), whose levels correlate with aging and risk of cardiovascular disease. In this study, healthy participants will consume the supplement for a 6-week period to determine if PAI-1 levels continue to be suppressed and also examine whether the supplement has an effect on other blood markers whose levels can change with aging or cardiovascular disease and may also be indicative or predictive of an illness.
CONDITIONS
Official Title
Effect of a Daily Supplement on Plasma PAI-1 Levels
Who Can Participate
Eligibility Criteria
You may qualify if you...
- People of any gender at least 18 years of age who do not have a history of acute or chronic cardiovascular illnesses are eligible.
You will not qualify if you...
- Younger than 18 years of age
- Currently pregnant (confirmed by pregnancy test for those capable)
- Using hormonal birth control
- Current smoker
- Allergy to ginger, muira puama, Paullinia cupana, or L-citrulline
- Previous use of Revactin4ae or RM
- History of serious cardiovascular events including heart attack or stroke
- History of coronary, cardiac, or carotid surgery such as stent, heart surgery, or endarterectomy
- Active cancer of any type except skin cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
UCLA
Los Angeles, California, United States, 90034
Actively Recruiting
2
UCLA The Men's Clinic
Santa Monica, California, United States, 90403
Actively Recruiting
Research Team
S
Sriram V Eleswarapu, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here